Literature DB >> 30292330

Meta-Analysis of the Impact of Strut Thickness on Outcomes in Patients With Drug-Eluting Stents in a Coronary Artery.

Micaela Iantorno1, Michael J Lipinski1, Hector M Garcia-Garcia1, Brian J Forrestal1, Toby Rogers2, Deepakraj Gajanana1, Kyle D Buchanan1, Rebecca Torguson1, William S Weintraub1, Ron Waksman3.   

Abstract

The aim of this network meta-analysis is to assess the impact of strut thickness on clinical outcomes in patients who underwent percutaneous coronary intervention. We searched Medline/PubMed and performed a Bayesian network meta-analysis to compare outcomes of patients who underwent percutaneous coronary intervention with drug-eluting stents (DES) of different strut thicknesses (ultrathin 60 to 80 μm; thin 81 to 100 μm; intermediate 101 to 120 μm; thick ≥120 μm). Studies comparing DES with similar strut thickness, bare metal stents, and fully bioresorbable scaffolds were excluded. Odds ratios with credible intervals (OR [CrIs]) were generated with random-effects models to compare outcomes. Our primary end point was stent thrombosis (ST). We identified 69 RCTs including 80,885 patients (ultrathin group = 10,219; thin group = 36,575; intermediate group = 11,399; thick group = 22,692). Mean age was 64 ± 11 years and 75% were male gender. When compared with thick-strut DES, ultrathin struts had significant less ST and myocardial infarction (OR 0.43 [CrI 0.27 to 0.68]; and OR 0.73 [CrI 0.62 to 0.92], respectively). Sensitivity analysis including only studies with permanent polymer DES gave similar results. Improvement in DES technology with thinner struts is associated with significant reduction in ST and myocardial infarction compared with thicker struts.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30292330     DOI: 10.1016/j.amjcard.2018.07.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.

Authors:  Rosaly A Buiten; Eline H Ploumen; Paolo Zocca; Carine J M Doggen; Liefke C van der Heijden; Marlies M Kok; Peter W Danse; Carl E Schotborgh; Martijn Scholte; Frits H A F de Man; Gerard C M Linssen; Clemens von Birgelen
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

Review 2.  Influences of Stent Design on In-Stent Restenosis and Major Cardiac Outcomes: A Scoping Review and Meta-Analysis.

Authors:  Omer Burak Istanbullu; Gulsen Akdogan
Journal:  Cardiovasc Eng Technol       Date:  2021-08-18       Impact factor: 2.495

3.  Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry.

Authors:  Matthias Bossard; Mehdi Madanchi; Dardan Avdijaj; Adrian Attinger-Toller; Giacomo Maria Cioffi; Thomas Seiler; Gregorio Tersalvi; Richard Kobza; Guido Schüpfer; Florim Cuculi
Journal:  Front Cardiovasc Med       Date:  2022-04-14

4.  Real-World Use Of Ultrathin-Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes.

Authors:  Prakash Ajmera; Ramesh Pothineni; Kamal Kumar Chawla; Sai Sudhakar Mantravadi; Pankaj Vinod Jariwala; Vinod Vijan; Vikrant Vijan
Journal:  Vasc Health Risk Manag       Date:  2019-10-18

Review 5.  Vascular Wall Reactions to Coronary Stents-Clinical Implications for Stent Failure.

Authors:  Tommaso Gori
Journal:  Life (Basel)       Date:  2021-01-17

6.  Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial.

Authors:  Gregor Fahrni; Ahmed Farah; Thomas Engstrøm; Søren Galatius; Franz Eberli; Peter Rickenbacher; David Conen; Christian Mueller; Otmar Pfister; Raphael Twerenbold; Michael Coslovsky; Marco Cattaneo; Christoph Kaiser; Norman Mangner; Gerhard Schuler; Matthias Pfisterer; Sven Möbius-Winkler; Raban V Jeger
Journal:  J Am Heart Assoc       Date:  2020-10-09       Impact factor: 5.501

7.  Twelve-month clinical outcomes of sirolimus-eluting stent in coronary artery disease: An experience in real-world Indian patients.

Authors:  Srikanth Nathani; Asif Raheem; Harish Sanadhya; Prakash Chandra Purohit; Ramesh Patel; Praveen K Alane; Deepeshkumar Agarwal; Ramanand Sinha
Journal:  Anatol J Cardiol       Date:  2020-12       Impact factor: 1.596

8.  Thin Strut CoCr Biodegradable Polymer Biolimus A9-Eluting Stents versus Thicker Strut Stainless Steel Biodegradable Polymer Biolimus A9-Eluting Stents: Two-Year Clinical Outcomes.

Authors:  Ian B A Menown; Mamas A Mamas; James M Cotton; David Hildick-Smith; Franz R Eberli; Gregor Leibundgut; Damras Tresukosol; Carlos Macaya; Samuel Copt; Sara Sadozai Slama; Keith G Oldroyd
Journal:  J Interv Cardiol       Date:  2021-04-01       Impact factor: 2.279

9.  Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold.

Authors:  Mehdi Madanchi; Giacomo Maria Cioffi; Adrian Attinger-Toller; Mathias Wolfrum; Federico Moccetti; Thomas Seiler; Luca Vercelli; Philipp Burkart; Stefan Toggweiler; Richard Kobza; Matthias Bossard; Florim Cuculi
Journal:  Open Heart       Date:  2021-09

10.  First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry.

Authors:  Ian B A Menown; Mamas A Mamas; James M Cotton; David Hildick-Smith; Franz R Eberli; Gregor Leibundgut; Damras Tresukosol; Carlos Macaya; Samuel Copt; Sara Sadozai Slama; Hans-Peter Stoll
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.